We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+34.37%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$893M
AUM Growth
+$128M
Cap. Flow
-$69.5M
Cap. Flow %
-7.78%
Top 10 Hldgs %
49.95%
Holding
59
New
4
Increased
15
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ACIU icon
AC Immune
ACIU
+$33.2M
2
CTMX icon
CytomX Therapeutics
CTMX
+$17.7M
3
MRSN
Mersana Therapeutics
MRSN
+$12.6M
4
REPL icon
Replimune Group
REPL
+$8.82M
5
OVID icon
Ovid Therapeutics
OVID
+$8.24M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$59.7M
2
ARRY
Array Biopharma Inc
ARRY
+$27.6M
3
XNCR icon
Xencor
XNCR
+$19.7M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$17.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$83.4M 9.34%
3,420,562
-1,323,500
-28% -$27.6M
MRUS
2
DELISTED
Merus
MRUS
$67.1M 7.51%
4,539,913
+25,000
+0.6% +$320K
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$45.2M 5.06%
564,965
-10,002
-2% -$739K
KURA icon
4
Kura Oncology
KURA
$804M
$41.4M 4.64%
2,495,156
-280,000
-10% -$4.31M
FPRX
5
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$41.1M 4.6%
3,064,346
+283,000
+10% +$3.23M
ACIU icon
6
AC Immune
ACIU
$226M
$37.6M 4.22%
7,455,534
+5,225,507
+234% +$33.2M
RCUS icon
7
Arcus Biosciences
RCUS
$3.5B
$35.1M 3.93%
2,810,223
+398,600
+17% +$4.33M
INFI
8
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$32.8M 3.67%
17,426,968
– –
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$31.6M 3.54%
431,700
-257,151
-37% -$17.5M
CYTK icon
10
Cytokinetics
CYTK
$10.7B
$30.8M 3.44%
3,801,817
-348,822
-8% -$2.56M
ARQL
11
DELISTED
Arqule Inc
ARQL
$30.2M 3.38%
6,308,746
+78,328
+1% +$302K
REPL icon
12
Replimune Group
REPL
$914M
$24.5M 2.74%
1,606,817
+707,200
+79% +$8.82M
XOMA
13
DELISTED
Xoma
XOMA
$21.9M 2.45%
1,769,029
– –
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
$20.8M 2.33%
238,609
+14,314
+6% +$1.05M
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$20.5M 2.3%
1,400,956
+185,229
+15% +$2.13M
CALA
16
DELISTED
Calithera Biosciences, Inc
CALA
$20.4M 2.28%
151,174
-13,740
-8% -$1.44M
CCXI
17
DELISTED
ChemoCentryx, Inc.
CCXI
$20.3M 2.28%
1,464,515
-5,223,008
-78% -$59.7M
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.13B
$18.2M 2.04%
1,788,774
– –
CNCE
19
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$16.7M 1.87%
1,385,487
+235,042
+20% +$3.46M
ANAB icon
20
AnaptysBio
ANAB
$1.57B
$16.1M 1.8%
220,265
– –
GLMD icon
21
Galmed Pharmaceuticals
GLMD
$4.82M
$15.3M 1.72%
10,436
– –
PTGX icon
22
Protagonist Therapeutics
PTGX
$8.7B
$14.1M 1.58%
1,123,255
-516,203
-31% -$4.56M
PVLA
23
Palvella Therapeutics
PVLA
$2.05B
$13.6M 1.52%
50,730
-42,494
-46% -$10.1M
MRSN
24
DELISTED
Mersana Therapeutics
MRSN
$13.2M 1.47%
+100,000
New +$12.6M
CTMX icon
25
CytomX Therapeutics
CTMX
$686M
$12.9M 1.44%
+1,198,000
New +$17.7M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2019 Portfolio in Review

As of Q1 2019, BVF Inc held 59 positions worth $893M, up 17% from $765M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

BVF Inc withdrew a net $69.5M in Q1 2019, closing 6 positions and reducing 14 holdings. Its most notable exit was Immune Design Corp., an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 83% a quarter earlier.

Against the trend, BVF Inc opened a new position in CytomX Therapeutics worth $12.9M.

  • BVF Inc's largest Q1 2019 buy was CytomX Therapeutics: 1,198,000 shares worth $12.9M.
  • BVF Inc added most to AC Immune in Q1 2019, an estimated $33.2M increase.
  • BVF Inc's biggest Q1 2019 reduction was ChemoCentryx, Inc., cutting an estimated $59.7M.
  • BVF Inc fully exited Immune Design Corp. in Q1 2019, selling an estimated $6.74M.
  • BVF Inc's ten largest holdings make up 50% of its $893M portfolio in Q1 2019.
  • BVF Inc opened 4 new positions and closed 6 in Q1 2019.
  • BVF Inc's portfolio value rose 17% quarter-over-quarter to $893M.

Based on BVF Inc's 13F filing for Q1 2019, filed 15 May 2019.